Bank Julius Baer & Co’s Intellia Therapeutics NTLA Stock Holding History

Bank Julius Baer & Co’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,897	Closed	-$52.2K	–	522
2024 Q1	$52.2K	Sell	1,897 -10	-0.5%	-$278	﹤0.01%	465
2023 Q4	$58.1K	Sell	1,907 -691	-27%	-$19.9K	﹤0.01%	471
2023 Q3	$82K	Sell	2,598 -7,102	-73%	-$276K	﹤0.01%	430
2023 Q2	$396K	Sell	9,700 -1,351	-12%	-$54.8K	﹤0.01%	361
2023 Q1	$412K	Buy	11,051 +1,600	+17%	+$62.8K	﹤0.01%	362
2022 Q4	$330K	Sell	9,451 -1,495	-14%	-$71.1K	﹤0.01%	376
2022 Q3	$613K	Buy	10,946 +1,503	+16%	+$93.2K	﹤0.01%	316
2022 Q2	$489K	Sell	9,443 -2,481	-21%	-$126K	﹤0.01%	343
2022 Q1	$867K	Sell	11,924 -1,600	-12%	-$136K	0.01%	297
2021 Q4	$1.6M	Buy	+13,524	New	+$1.69M	0.01%	297
2021 Q1	–	Sell	-6,563	Closed	-$357K	–	867
2020 Q4	$357K	Buy	+6,563	New	+$238K	﹤0.01%	497

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank Julius Baer & Co's NTLA Position: Q2 2024 in Review

Bank Julius Baer & Co sold out of Intellia Therapeutics (NTLA) in Q2 2024, closing a stake of 1,897 shares — an estimated $52.2K sold.

Bank Julius Baer & Co first reported a position in NTLA in Q4 2020 and held it in 11 quarters. The position peaked at $1.6M in Q4 2021. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2024.

Bank Julius Baer & Co reported no remaining Intellia Therapeutics position as of Q2 2024 after selling out during the quarter.
Bank Julius Baer & Co sold 1,897 Intellia Therapeutics shares in Q2 2024, an estimated $52.2K.
Bank Julius Baer & Co first reported a position in Intellia Therapeutics in Q4 2020 and held it in 11 quarters.
Bank Julius Baer & Co's Intellia Therapeutics position peaked at $1.6M in Q4 2021.
290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2024.

Based on Bank Julius Baer & Co's 13F filing for Q2 2024, filed 14 Aug 2024.